Exchange of $70.238M (plus interest) of convertible notes into 10,401,309 shares of common stock at $7.20 per share. $6.809M Private Placement representing 945,819 shares of common stock at $7.20 per share. BELGRADE, Mont., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the exchange of Xtant’s outstanding 6.00% convertible senior unsecured notes due 202…

Approval of the issuance of new shares of common stock, as required by the NYSE American. Approval of an amendment to its certificate of incorporation, enabling its previously announced 1:12 reverse stock split. Approval of new directors to serve on its board. BELGRADE, Mont., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the results of its Special Meeti…

Conversion of $1.627M (plus interest) of convertible notes into common stock Exchange of $70.238M (plus interest) of convertible notes into common stock Upon stockholder approval, amendment of Certificate of Incorporation to effect reverse stock split of common stock Private placement of approximately $6.809M of common stock Completion of transaction anticipated to allow Xtant to meet liquidity needs and reposition itself for long-term growth. BELGRADE, Mont., Jan. 18, 2018 (GLOBE NEWSWIRE) -…

Company restructuring efforts continue to gain traction towards profitability Third Quarter 2017 Highlights Reported third quarter 2017 revenue of $19.8 million compared to $23.1 million reported during the third quarter of 2016 Operating Expenses decreased 17% to $14.9 million, compared to $17.9 million reported during the third quarter of 2016 Third quarter 2017 EBITDA of $1.4 million compared to $0.7 million reported during the third quarter of 2016   Company management to host conference…

BELGRADE, Mont., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, announced that it has postponed the release of its third quarter 2017 financial results, originally scheduled for Wednesday, November 8, 2017, and conference call, originally scheduled for Thursday, November 9, 2017. The Company now plans to release its third quarter 2017 financial results in conjunction with t…

BELGRADE, Mont., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced it has entered into a distribution agreement with curasan, Inc. adding a premium line of synthetic scaffolds to its biologics portfolio.  Matriform, Xtant’s brand of the curasan synthetic product portfolio for orthopedic applications, consists of a composition of pure phase Beta-Tricalcium Ph…

BELGRADE, Mont., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the third quarter ended September 30, 2017, after the close of the financial markets on Wednesday, November 8th, 2017. An accompanying conference call will be conducted by Carl O'Connell, Chief Executive Officer and President, and Laura Kendall, Int…

BELGRADE, Mont., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, announced it will be showcasing its portfolio, featuring new technologies, at the 2017 annual North American Spine Society (NASS) Annual Meeting in Orlando, FL.  Xtant will have a technical exhibit booth located at #1118, and will be hosting a cadaveric product demonstration highlighting proprietary hardware a…

Expected approximate $2 million savings when implemented BELGRADE, Mont., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the closure of its Dayton, Ohio facility and the transitioning of its fixation operations to the Company’s headquarters in Belgrade, Montana. This decision will allow the Company to align operations with the current and future needs of i…

BELGRADE, Mont., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that the U.S. Food and Drug Administration (FDA) has cleared product line extensions for the Irix-A interbody spacer.  The clearance provides for the addition of three additional size configurations for an expanded market opportunity, and importantly, for use with allograft.  This clearance i…

Company Continues to Take Steps During Restructuring to Build for Future Growth BELGRADE, Mont., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today reported its financial results for the quarter ended June 30th, 2017. The Company reported Second Quarter 2017 revenue of approximately $21.4 million and an EBITDA loss of approximately ($2.1) million for the period. Reven…

BELGRADE, Mont., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that the U.S. Food and Drug Administration (FDA) has cleared product line extensions for the Calix-C family of cervical interbody cages.  The clearance provides for the addition of two larger footprints and importantly, for use with allograft.  This clearance strengthens Xtant Medical’s focu…